SCHEDULE 13G/A: Baillie Gifford & Co Discloses Reduced Passive Stake in Adaptimmune Therapeutics PLC

Baillie Gifford & Co has reported a 4.6% passive ownership stake in Adaptimmune Therapeutics PLC as of December 31, 2024, indicating a reduction below the 5% threshold.

Summary

• Baillie Gifford & Co, a UK-based investment adviser, filed an Amendment No. 5 to Schedule 13G regarding its beneficial ownership in Adaptimmune Therapeutics PLC.
• As of December 31, 2024, Baillie Gifford & Co beneficially owned 70,914,570 ordinary shares of Adaptimmune Therapeutics PLC.
• This ownership represents 4.6% of the class of Common Stock, a decrease from previous filings that would have placed them above the 5% threshold.
• The shares are held as 11,819,095 American Depositary Shares (ADS), with six ordinary shares representing one ADS.
• Baillie Gifford & Co maintains sole voting power and sole dispositive power over these 70,914,570 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a passive ownership stake. While the continued presence of a major investor like Baillie Gifford is mildly positive, the decrease below 5% (implied by Amendment No. 5 and Item 5) could be seen as neutral to slightly negative, but it's a passive investment, so not a strong signal. Overall, it's a neutral regulatory update.

Positives

• Baillie Gifford & Co, a prominent investment adviser, continues to hold a substantial passive stake in Adaptimmune Therapeutics PLC, signaling ongoing confidence in the company.
• The certification confirms the investment is for ordinary business purposes and not for control, suggesting stability in the ownership structure and no immediate activist intentions.

Negatives

• The filing, being an Amendment No. 5 and reporting 4.6% ownership, indicates that Baillie Gifford & Co's stake has decreased below the 5% threshold, which might be interpreted as a slight reduction in conviction or portfolio rebalancing.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Adaptimmune Therapeutics PLC's future performance or Baillie Gifford & Co's investment strategy beyond the passive nature of the holding.

Management Comments

• The filing includes a certification by Baillie Gifford & Co that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a routine disclosure of a significant institutional investor's passive stake in a biotechnology company. Such disclosures provide transparency on major shareholdings but do not typically offer insights into the operational or strategic trends within the broader biotechnology or pharmaceutical industry.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of beneficial ownership and does not provide financial or operational results that can be directly compared to industry benchmarks or specific comparable companies/projects. It indicates a significant institutional investment in Adaptimmune Therapeutics PLC, a company operating in the biotechnology sector, which is common for large asset managers like Baillie Gifford & Co.

Stakeholder Impact

• Shareholders: Provides transparency on a significant institutional holding. The slight decrease in percentage (implied by falling below 5%) might be noted but is not necessarily indicative of a change in company fundamentals.
• Employees, Customers, Suppliers, Creditors: No direct impact from this ownership disclosure.

Next Steps

• The document does not specify any future actions, events, or milestones for Adaptimmune Therapeutics PLC or Baillie Gifford & Co beyond the regulatory requirement to update beneficial ownership if certain thresholds are met.

Key Dates

Keywords

Adaptimmune Therapeutics PLC, Baillie Gifford & Co, Schedule 13G, Beneficial Ownership, Common Stock, ADS, Investment Adviser, Passive Investment, Shareholding